Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL

Clinical trial NCT07441993 · RECRUITING

Trial details

NCT number: NCT07441993
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Marginal Zone Lymphoma

Start date: 2026-01-05
Primary completion: 2027-12-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.